Early access to promising cancer pill before official approval
NCT ID NCT03123029
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program offers early access to venetoclax, a targeted cancer pill, for people with certain blood cancers like leukemia or lymphoma who have no other good treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved in all regions, so availability depends on location.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax (a targeted cancer pill)
- What this could lead to
- If it works, this could provide early access to a treatment that may help control certain blood cancers.
- What could go wrong
- This is an expanded access program, not a formal trial, so evidence is limited. The drug is investigational and may not work for everyone; risks include side effects like tumor lysis syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- A hidden warning in your wrist? surgery may reveal heart risk
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can 3D-Printed models unlock personalized blood cancer therapies?